{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Hormone Therapy Agent[C147908]" in comments (approximate match)
Status:
US Approved Rx
(2014)
Source:
ANDA200910
(2014)
Source URL:
First approved in 2001
Source:
ORTHO EVRA by JANSSEN PHARMS
Source URL:
Class:
MIXTURE
Targets:
Conditions:
Norelgestromin, the progestin, is the active metabolite of norgestimate and is structurally related to 19-nortestosterone. Norgestimate and norelgestromin mimic the physiologic effects of progesterone at the progesterone receptor. Johnson & Johnson developed an adhesive female contraceptive patch that contains ethinylestradiol (0.75mg) and the progestogen norelgestromin (6mg). his product is a combination contraceptive acting via the inhibition gonadotropins. Its primary mechanism of action involves the suppression of ovulation, including changes in the cervical mucus and endometrium. The patch delivers a continuous flow of hormones through the skin and into the bloodstream. The contraceptive patch is available in countries worldwide.
Status:
US Approved Rx
(2015)
Source:
ANDA200383
(2015)
Source URL:
First approved in 1989
Source:
ORTHO CYCLEN-21 by JANSSEN PHARMS
Source URL:
Class:
MIXTURE
Targets:
Norgestimate is a steroidal progestin of the 19-nortestosterone group that is used in combination with ethinylestradiol as an oral contraceptive and for treatment of acne. and in combination with estradiol in menopausal hormone replacement therapy. Norgestimate shows high selectivity for the progesterone receptor and low androgenic activity.
Status:
US Approved Rx
(2002)
Source:
BLA021484
(2002)
Source URL:
First approved in 1986
Source:
METRODIN by SERONO
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2004)
Source:
BLA021663
(2004)
Source URL:
First approved in 1975
Source:
PERGONAL by SERONO
Source URL:
Class:
MIXTURE
Status:
US Previously Marketed
Source:
ENJUVIA by DURAMED
(2004)
Source URL:
First approved in 2004
Source:
ENJUVIA by DURAMED
Source URL:
Class:
MIXTURE
Status:
US Previously Marketed
Source:
CENESTIN by ASPEN
(1999)
Source URL:
First approved in 1999
Source:
CENESTIN by ASPEN
Source URL:
Class:
MIXTURE
Status:
US Previously Marketed
Source:
SECRETIN-FERRING by FERRING
(1981)
Source URL:
First approved in 1981
Source:
SECRETIN-FERRING by FERRING
Source URL:
Class:
MIXTURE
Secretin is a peptide hormone produced by S-cells of the small intestinal mucosa and involved in the regulation of pancreatic secretory activity. S-cells that are located in the mucous membrane of the duodenum and in the proximal part of the jejunum secrete the polypeptide prosecretin, an inactive precursor of secretin, which turns into secretin by the action of hydrochloric acid of the gastric juice. Being absorbed into the blood, secretin reaches the pancreas and pancreatic centroacinar cells have secretin receptors in their plasma membrane. As secretin binds to these receptors, it enhances the secretion of bicarbonate-rich fluid that flows into the intestine. Bicarbonate is a base that neutralizes the acid, thus establishing a pH favorable to the action of other digestive enzymes in the small intestine. Secretin also increases water and bicarbonate secretion from duodenal Brunner's glands to buffer the incoming protons of the acidic chyme and also reduces acid secretion by parietal cells of the stomach. Secretin is used in a diagnostic test for pancreatic function.
Status:
US Previously Marketed
Source:
MENRIUM 5-2 by ROCHE
(1966)
Source URL:
First approved in 1966
Source:
MENRIUM 5-2 by ROCHE
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 2010
Source:
ARMOUR THYROID by Rebel Distributors Corp
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT03177538: Phase 4 Interventional Completed Infertility, Female
(2017)
Source URL:
First approved in 2005
Source:
PLUSET by Minitube of America, Inc.
Source URL:
Class:
MIXTURE